Hangzhou Tigermed Consulting (HKG:3347, SHE:300347) expects a net profit attributable to shareholders between 380 million yuan and 570 million yuan for 2024, 72% to 81% lower than 2.02 billion yuan logged for the preceding year, a Friday Hong Kong bourse filing said.
The medical laboratory company attributed the anticipated decline to a significant decrease in investment income, market competition, and a significant decrease in non-recurring gains and losses during the reporting year.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。